All you need to get started with ETF selection and analysis. Create your account now →

Help us improve your experience. Please confirm your investor type:

ETF What's Up

Don’t Miss a Move in the ETF Market

Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.

ETF What's Up

You may unsubscribe at any time by clicking the “unsubscribe” link within the emailed newsletter. By signing up, you agree to our Privacy Policy and Terms and Conditions.

ETF screener

IDNA ETF · iShares Genomics Immunology and Healthcare ETF

The IDNA Exchange Traded Fund (ETF) is provided by iShares. It is built to track an index: NYSE FactSet Global Genomics and Immuno Biopharma Index. The IDNA ETF provides physical exposure, so by buying it you actually own parts of all the 51 underlying holdings. This share class generates a stream of income by distributing dividends.
Last update 5/1/2026, 1:30 PM UTC
LIVE
CLOSED
This fund is part ofBioTech & Genomics1M perf.+9.43%
Last price
$29.32
1M perf.
+0.64%
1M flows
+€6.6M
AuM
€136M
E/R
0.47%
Rating
ESG Consensus®
esg grade icon
IDNA
$29.32

Performance & flows

Segment for quartile rank
February 2, 2026 → May 1, 2026
0-15-10-505%MARAPRMAYMARAPRMAY
Create a free account to view the flows graph
IDNA
$29.31
+1.55%
BioTech & Genomics
-2.17%

Historic performance and flows

1M3M1Y3Y5YMTDQTDYTD
Perf.
+0.64%
icon
+1.55%
icon
+43.18%
icon
+27.97%
icon
-35.68%
-0.44%
+1.50%
+11.96%
icon
Flows

Key fund info

Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) · 
Main characteristics
Issuer
CUSIP
46435U192
ISIN
US46435U1925
AuM
€136M
icon
E/R
0.47%
icon
Replication rating
ESG Consensus®
esg grade icon
More details
NAV
5/1/2026
$29.31
1D NAV change
-0.44%
Dividend policy
Replication method
Direct (Physical)
Replication model
Full replication
No. of holdings
51
Inception date
6/11/2019
Jurisdiction
United States
Distribution
United States
Legal structure
Unit Investment Trust
Base currency
USD
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Investment strategy
The iShares Genomics Immunology and Healthcare ETF seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
half moonhalf moon double
New to Trackinsight?
For individual investors

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.
More fund data
Compare up to 3 funds
More screener filters
Choose your own screener columns from 100+ metrics
Lists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring
For professional investors

Trackinsight
Enterprise

Trackinsight Enterprise addresses the everyday operational, regulatory, and analytical pain points faced by professional and institutional ETF investors, from selection to execution.
Request a free trial
More professional services:ETF Data ServicesDue Diligence Services

Similar ETFs in your region

XDNA
1M perf.
-1.53%
E/R
0.44%
2B78
1M perf.
-2.43%
E/R
0.4%
LIV
1M perf.
-2.27%
E/R
0.75%
HTEC
1M perf.
+4.94%
E/R
0.8%
PJP
1M perf.
+0.84%
E/R
0.57%

Advertisement

Risk profile

Segment for quartile rank

Historical risk/return profile

3M1Y3Y5Y
Returns
+1.55%
icon
+43.18%
icon
+27.97%
icon
-35.68%
Volatility
Perf./Volatility
Max drawdown
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
More exposure metrics are available, exclusively in Trackinsight Enterprise

Exposure

Countries
USA
63.25%
France
8.84%
Japan
6.66%
Switzerland
5.32%
Germany
4.31%
United Kingdom
4.16%
Denmark
3.07%
China
2.19%
Unavailable
0.33%
Other
1.87%
Sectors
Health Care
90.61%
Unavailable
9.39%
Diversification
Total weight of top 15 holdings out of 51
Top 15 holdings
Data as of March 31, 2026
MODERNA INC
ARCELLX
IPSEN PROMESSES
TAKEDA PHARMACEUTICAL
REVOLUTION MEDICINES INC
MERCK & CO INC
BAYER AG
GSK PLC
Create a free account to view top holdings
REGENERON PHARMACEUTICALS
CH1499059983
VERTEX PHARMACEUTICALS
EXELIXIS
SANOFI SA
BIONTECH SE ADR
INCYTE
Create a free account to view top holdings
More risk metrics are available, exclusively in Trackinsight Enterprise

Sustainability

Integrates ESG criteria
No
SDG

ESG Consensus® by Conser

Data as of February 27, 2026
Methodology

Our partner Conser gathers the industry's consensus on the business practices of the underlying holdings. We have computed the following metrics about IDNA ETF's sustainability, based on their methodology.

Learn more about Conser

ESG Consensus®
esg grade icon

ESG Consensus® is based on the Final Sustainability Grade, which itself consists of 10 grades. Our partner Conser calculates the exact grade, based on market intelligence, using their proprietary ESG Consensus® methodology.


IDNA’s has a Final Sustainability Grade of either B+, B, or B-.

This fund’s exact Final Sustainability Grade is available in Trackinsight Enterprise.
Learn more about Trackinsight Enterprise
Holdings review
83.22% of holdings have positive scoring
17.12% of holdings have negative scoring
9.98%
56.63%
16.61%
10.74%
Consensus levels
Strong
Medium
Weak
More sustainability metrics are available, exclusively in Trackinsight Enterprise

Replication

Trackinsight replication rating:
1-year trailing difference
As of April 30, 2026
Create a free account to view the replication graph
IDNA
N/A
Replication quality
Calculated over 12m, as of April 30, 2026
Tracking error
Tracking difference
1-year cumulative return difference
Best
Worst
Daily return difference
Average
Worst
Replication information
Index
Index ticker
Index dividend policy
Replication method
Replication model

Issuer

iShares
iShares ID Card
Number of funds
1742
Total AuM
€5.19T
Expense ratio range
0.03% - 1.51%
Average expense ratio
0.284%

Frequently asked questions about IDNA

What does iShares Genomics Immunology and Healthcare ETF, IDNA, invest in?

IDNA is a Passive ETF. This ETF provides exposure to Global Equities.

Which benchmark or index does IDNA replicate?

IDNA tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index NTR - USD, through a full replication replication method.

What is the Total Expense ratio (TER) of IDNA?

IDNA carries a total expense ratio (TER) of 0.47%, indicating the annual cost for holding the fund.

When was IDNA launched?

IDNA was introduced to the market on June 11, 2019. It trades on United States

Who is the ETF issuer of IDNA?

iShares Genomics Immunology and Healthcare ETF, IDNA, is provided by iShares. Learn more about iShares here.

What is the current assets under management (AUM) of IDNA?

IDNA oversees €136M in assets as of May 1, 2026.

How has IDNA performed lately?

Based on data from May 1, 2026, IDNA returned 0.64% over the past month, 1.55% over the last three months and 11.96% year-to-date.

What are the latest inflows or outflows for IDNA?

As of May 1, 2026, IDNA recorded net flows of +€6.5M over the last month and +€12M year-to-date.

Does IDNA distribute dividends?

IDNA follows a distributing dividend policy, meaning it pays out income to investors. As of May 1, 2026, its 12-month trailing yield was 1.05%.

What are the main country or region exposures of IDNA?

As of March 31, 2026, IDNA has significant geographic allocations in USA, France and Japan.

In which sector or theme does IDNA invest in?

As of March 31, 2026, IDNA focuses largely on Health Care.

How many securities does IDNA hold and how diversified is it?

As of March 31, 2026, IDNA holds 51 positions in its portfolio, with 64.09% of assets concentrated in its top 15 holdings.

What are the main positions in IDNA?

As of March 31, 2026, IDNA top three holdings include MODERNA INC, ARCELLX and IPSEN PROMESSES.

What is the base currency of IDNA?

The base currency of IDNA is USD.

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight